Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Shares of Prothena Corporation PRTA plummeted 53.5% year to date compared with the industry’s decline of 0.6%. The recent ...

Tempus AI TEM is entering a phase of strong operating momentum, backed by significant acceleration in both revenues and gross profit. This trend became particularly clear in the company’s last two ...

Peter Moulding joined a clinical trial for the drug AMP945 not really knowing whether it would help him with deadly stage ...

Interest in autonomous agents is skyrocketing. Here, CIOs from finance, retail, and healthcare discuss how they see the ...

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

The combination of climate change and pathogen expansion could be fueling a surge in infectious diseases. GEN consulted ...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence ...

A patient shares how an event about clinical trials at Moores Cancer Center brought a community together to educate and ...